{
    "clinical_study": {
        "@rank": "78824", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant FOLFIRINOX Regimen", 
            "arm_group_type": "Other", 
            "description": "Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection"
        }, 
        "brief_summary": {
            "textblock": "A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic\n      pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)"
        }, 
        "brief_title": "Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreas Cancer", 
            "Localized Pancreas Cancer", 
            "Non-metastatic Pancreas Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients with pancreas cancer will be enrolled and treated with a planned course of 6 cycles\n      (3 months) of chemotherapy with FOLFIRINOX prior to undergoing surgical resection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  Male or non-pregnant and non-lactating female\n\n          -  Histologically or cytologically confirmed adenocarcinoma of pancreas\n\n          -  Patients must have satisfactory blood counts and blood chemistry levels at baseline\n             (refer to Appendix 2, Study Laboratory References Range).\n\n          -  Patient has Eastern Cooperative Oncology Group(ECOG) Performance Status 0 to 1 (refer\n             to Appendix 7):\n\n          -  0 - Asymptomatic (Fully active, able to carry on all predisease activities without\n             restriction)\n\n          -  1 - Symptomatic but completely ambulatory (Restricted in physically strenuous\n             activity but ambulatory and able to carry out work of a light or sedentary nature.\n             For example, light housework, office work)\n\n          -  Signed study consent form\n\n        Exclusion Criteria:\n\n          -  <18 years of age\n\n          -  Pregnant or lactating female\n\n          -  Patient has islet cell neoplasms\n\n          -  Patient has known brain metastases\n\n          -  Patient has metastatic disease\n\n          -  Active secondary malignancies\n\n          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic\n             therapy\n\n          -  Known infection with hepatitis B, hepatitis C, or cirrhosis\n\n          -  Major surgery or vascular device placement (excluding ports for IV\n             medication/chemotherapy) within 2 weeks prior to Day 1 of treatment in study\n\n          -  Prior chemotherapy or radiation for pancreatic cancer\n\n          -  History of allergy or hypersensitivity to the study drugs\n\n          -  Patient is enrolled in any outside (outside Baylor University Medical Center or Texas\n             Oncology) clinical protocol or investigational trial\n\n          -  Significant cardiac disease as defined as New York Heart Association (NYHA)\n             classification III or IV, uncontrolled congestive heart failure (CHF), or prior\n             myocardial infarction (MI) last 6-months\n\n          -  Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal\n             radiation which in the opinion of the investigator may place the patient at increased\n             risk\n\n          -  Peripheral sensory neuropathy \u2265 to grade 2 at baseline\n\n          -  Significant co-morbidities deemed by investigator as unsuitable for\n             participation/enrollment\n\n          -  Study consent form not signed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771146", 
            "org_study_id": "012-180"
        }, 
        "intervention": {
            "arm_group_label": "Neoadjuvant FOLFIRINOX Regimen", 
            "description": "6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin\u00ae (Oxaliplatin)\t85 mg per square meter 2-hour IV infusion Camptosar\u00ae (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion", 
            "intervention_name": "FOLFIRINOX Regimen", 
            "intervention_type": "Drug", 
            "other_name": [
                "FOLFIRINOX", 
                "Oxaliplatin", 
                "Irinotecan", 
                "5-FU", 
                "Eloxatin", 
                "Camptosar", 
                "Adrucil"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Camptothecin", 
                "Pancreatin", 
                "Pancrelipase", 
                "Leucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-metastatic Pancreas Cancer", 
            "Pancreatic Cancer", 
            "Cancer of Pancreas", 
            "Adenocarcinoma of Pancreas", 
            "Neoadjuvant"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "contact": {
                "email": "scott.celinski@Baylorhealth.edu", 
                "last_name": "Scott Celinski, MD", 
                "phone": "214-820-2302"
            }, 
            "contact_backup": {
                "email": "angelia.drake@baylorhealth.edu", 
                "last_name": "Angelia Drake, RN,BSN", 
                "phone": "214-820-2506"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75246"
                }, 
                "name": "Baylor University Medical Center - Texas Oncology"
            }, 
            "investigator": [
                {
                    "last_name": "Carlos Becerra, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keith Cavaness, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Preskitt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)", 
        "overall_contact": {
            "email": "scott.celinski@baylorhealth.edu", 
            "last_name": "Scott Celinski, MD", 
            "phone": "214-820-2302"
        }, 
        "overall_contact_backup": {
            "email": "angelia.drake@baylorhealth.edu", 
            "last_name": "Angelia Drake, RN,BSN", 
            "phone": "214-820-2506"
        }, 
        "overall_official": {
            "affiliation": "Baylor Health Care System", 
            "last_name": "Scott Celinski, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "\u2022 The length of time from diagnosis (enrollment) to death", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "\u2022 Overall Survival rate defined by the % of people who are alive for a certain period of time after diagnosis", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "\u2022 R0 resection as defined as microscopically negative margins", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Baylor Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}